Adcetris gets Priority Review for first-line classical Hodgkin's lymphoma

Seattle Genetics (NASDAQ:SGEN) said FDA accepted and granted Priority Review to an sBLA for Adcetris brentuximab vedotin (SGN-35) as

Read the full 194 word article

User Sign In